This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
Talk:Dextromethorphan: Difference between revisions
>Artoria2e5 m <references/> |
>Artoria2e5 edit comment |
||
| Line 56: | Line 56: | ||
On the other hand, [[Wikipedia:Dextromethorphan/bupropion|dextromethorphan/bupropion]] is an approved combination drug; each ''extended-release'' tablet contains 45 mg DXM and 105 mg bupropion. The maximum dose for depression is set at 2 tablets per day, spaced at least 8 hours apart.<ref name=p37859435>McCarthy, B; Bunn, H; Santalucia, M; Wilmouth, C; Muzyk, A; Smith, CM (30 November 2023). "Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder". Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. 21 (4): 609–616. doi:10.9758/cpn.23.1081. PMID 37859435. PMC [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc10591164/ 10591164]. Retrieved via PMC.</ref> Although this combination drug is safe enough to be approved, the safety of an instant-release combination and of higher doses remains a concern. | On the other hand, [[Wikipedia:Dextromethorphan/bupropion|dextromethorphan/bupropion]] is an approved combination drug; each ''extended-release'' tablet contains 45 mg DXM and 105 mg bupropion. The maximum dose for depression is set at 2 tablets per day, spaced at least 8 hours apart.<ref name=p37859435>McCarthy, B; Bunn, H; Santalucia, M; Wilmouth, C; Muzyk, A; Smith, CM (30 November 2023). "Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder". Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. 21 (4): 609–616. doi:10.9758/cpn.23.1081. PMID 37859435. PMC [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc10591164/ 10591164]. Retrieved via PMC.</ref> Although this combination drug is safe enough to be approved, the safety of an instant-release combination and of higher doses remains a concern. | ||
</blockquote> | </blockquote> | ||
So [[User:JH556|JH556]], I ''guess'' the relative safety has something to do with it being extended-release. I don't know how much safety margin for precaution goes into the "space doses at least 8hrs apart" disclaimer, but it has to be... decent enough? | |||
The existing source https://sci-hub.se/10.1097/01.jcp.0000162805.46453.e3 speculates at a risk, but it (and the deleted line about Bupropion) does not go into the psychoactive consequences of having less DXM convert to dextrorphan. This should produce a very significant change in the subjective effect, as dextrorphan is much more potent at the hallucinogenic NMDAR than DXM. | The existing source https://sci-hub.se/10.1097/01.jcp.0000162805.46453.e3 speculates at a risk, but it (and the deleted line about Bupropion) does not go into the psychoactive consequences of having less DXM convert to dextrorphan. This should produce a very significant change in the subjective effect, as dextrorphan is much more potent at the hallucinogenic NMDAR than DXM. | ||